| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2016PLoSO..1157580S |
| P356 | DOI | 10.1371/JOURNAL.PONE.0157580 |
| P932 | PMC publication ID | 4917109 |
| P698 | PubMed publication ID | 27333187 |
| P50 | author | Yoshimi Nakagawa | Q87764970 |
| Hitoshi Shimano | Q87968959 | ||
| Masaaki Isaka | Q89084715 | ||
| Yoshinori Takeuchi | Q89817177 | ||
| Takashi Matsuzaka | Q90787935 | ||
| Shigeru Yatoh | Q114444342 | ||
| Noriko Suzuki-Kemuriyama | Q114444345 | ||
| Motoko Kuba | Q114444346 | ||
| Song-Iee Han | Q114444347 | ||
| Kazuto Kobayashi | Q68067035 | ||
| Hirohito Sone | Q39956334 | ||
| Naoya Yahagi | Q42403191 | ||
| P2093 | author name string | Hiroshi Ohno | |
| Hiroaki Suzuki | |||
| Nobuhiro Yamada | |||
| Katsuhiro Miyajima | |||
| Hitoshi Iwasaki | |||
| Dai Nakae | |||
| P2860 | cites work | Are all n-3 polyunsaturated fatty acids created equal? | Q27497371 |
| Nonalcoholic fatty liver disease: a feature of the metabolic syndrome | Q28208772 | ||
| Regulation of hepatic lipogenesis by the transcription factor XBP1 | Q28507784 | ||
| Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor alpha activity in rat primary hepatocytes | Q28565367 | ||
| Steatohepatitis: a tale of two "hits"? | Q29547771 | ||
| Molecular mediators of hepatic steatosis and liver injury | Q29616709 | ||
| Nonalcoholic fatty liver disease | Q29619354 | ||
| Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis | Q29619888 | ||
| Lipotoxicity in the liver. | Q30355131 | ||
| Epidemiology and natural history of non-alcoholic steatohepatitis | Q30449204 | ||
| Fat-specific protein 27, a novel lipid droplet protein that enhances triglyceride storage | Q42824398 | ||
| Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats | Q44785856 | ||
| A lipidomic analysis of nonalcoholic fatty liver disease. | Q44931121 | ||
| No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial | Q44997998 | ||
| Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. | Q46955928 | ||
| Elovl6 promotes nonalcoholic steatohepatitis | Q58207361 | ||
| A Crucial Role of Sterol Regulatory Element-binding Protein-1 in the Regulation of Lipogenic Gene Expression by Polyunsaturated Fatty Acids | Q60642311 | ||
| Prostaglandins, thromboxanes, and leukotrienes in inflammation | Q69881376 | ||
| Fatty liver: think globally | Q84135789 | ||
| Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis | Q85307305 | ||
| Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial | Q85319932 | ||
| Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study | Q87417591 | ||
| C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis | Q33750735 | ||
| Leukotrienes: Mediators of Immediate Hypersensitivity Reactions and Inflammation | Q34254403 | ||
| Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease | Q34357996 | ||
| n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases | Q34569101 | ||
| 4-Hydroxy hexenal derived from docosahexaenoic acid protects endothelial cells via Nrf2 activation | Q34920009 | ||
| Human fatty liver disease: old questions and new insights | Q35588477 | ||
| Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA. | Q35753377 | ||
| Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis | Q35757087 | ||
| The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). | Q35907960 | ||
| Absence of Elovl6 attenuates steatohepatitis but promotes gallstone formation in a lithogenic diet-fed Ldlr(-/-) mouse model | Q36333590 | ||
| Nonalcoholic fatty liver disease: from steatosis to cirrhosis | Q36382279 | ||
| Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice | Q36483906 | ||
| Distribution, interconversion, and dose response of n-3 fatty acids in humans | Q36536062 | ||
| Fish oil -- how does it reduce plasma triglycerides? | Q36584568 | ||
| Desaturase and elongase-limiting endogenous long-chain polyunsaturated fatty acid biosynthesis | Q36623100 | ||
| Fat-specific protein 27 regulates storage of triacylglycerol | Q36662761 | ||
| Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis. | Q37017917 | ||
| The opposing effects of n-3 and n-6 fatty acids | Q37058217 | ||
| N-3 polyunsaturated fatty acid regulation of hepatic gene transcription | Q37156302 | ||
| The epidemiology of nonalcoholic fatty liver disease: a global perspective | Q37310275 | ||
| Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity | Q37393336 | ||
| The key roles of elongases and desaturases in mammalian fatty acid metabolism: Insights from transgenic mice. | Q37657815 | ||
| Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites | Q37777696 | ||
| n-3 fatty acids in cardiovascular disease | Q37893165 | ||
| Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology | Q38176690 | ||
| Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. | Q38297724 | ||
| Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression | Q38347368 | ||
| Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease | Q38358419 | ||
| Polyunsaturated fatty acids selectively suppress sterol regulatory element-binding protein-1 through proteolytic processing and autoloop regulatory circuit. | Q39741460 | ||
| Prostaglandins, Arachidonic Acid, and Inflammation | Q40122354 | ||
| Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients | Q40370241 | ||
| Eicosapentaenoic acid attenuates hepatic accumulation of cholesterol esters but aggravates liver injury and inflammation in mice fed a cholate-supplemented high-fat diet | Q42711327 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver disease | Q929737 |
| metabolic dysfunction–associated steatotic liver disease | Q1546498 | ||
| atherosclerosis | Q12252367 | ||
| non-alcoholic fatty liver | Q66299798 | ||
| P304 | page(s) | e0157580 | |
| P577 | publication date | 2016-06-22 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice | |
| P478 | volume | 11 |
| Q50153963 | Association of Blood Fatty Acid Composition and Dietary Pattern with the Risk of Non-Alcoholic Fatty Liver Disease in Patients Who Underwent Cholecystectomy |
| Q64972868 | Dietary Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) Operate by Different Mechanisms to Modulate Hepatic Steatosis and Hyperinsulemia in fa/fa Zucker Rats. |
| Q60950066 | Effective Food Ingredients for Fatty Liver: Soy Protein β-Conglycinin and Fish Oil |
| Q36154945 | Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials |
| Q104461516 | Effects of dietary oils prepared from the internal organs of the Japanese giant scallop (Patinopecten yessoensis) on cholesterol metabolism in obese type-II diabetic KK-Ay mice |
| Q48304928 | Effects of rosa mosqueta oil supplementation in lipogenic markers associated with prevention of liver steatosis. |
| Q50080490 | Eicosapentaenoic acid attenuates obesity-related hepatocellular carcinogenesis |
| Q38705146 | Eicosapentaenoic acid down-regulates expression of the selenoprotein P gene by inhibiting SREBP-1c protein independently of the AMP-activated protein kinase pathway in H4IIEC3 hepatocytes |
| Q42283305 | Eicosapentaenoic acid shows anti-inflammatory effect via GPR120 in 3T3-L1 adipocytes and attenuates adipose tissue inflammation in diet-induced obese mice |
| Q33743274 | Fat content, fatty acid pattern and iron content in livers of turkeys with hepatic lipidosis. |
| Q89224431 | Nutrients, Nutraceuticals, and Xenobiotics Affecting Renal Health |
| Q39445103 | Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease |
| Q64913342 | Physiological effects of an oil rich in γ-linolenic acid on hepatic fatty acid oxidation and serum lipid levels in genetically hyperlipidemic mice. |
| Q47120918 | Retroconversion is a minor contributor to increases in eicosapentaenoic acid following docosahexaenoic acid feeding as determined by compound specific isotope analysis in rat liver. |
| Q60915982 | The cirrhotic liver is depleted of docosahexaenoic acid (DHA), a key modulator of NF-κB and TGFβ pathways in hepatic stellate cells |
Search more.